Alpha Tau to Participate in October Investor Conferences
JERUSALEM, October 5, 2026 — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026. Event: Fall Focus: Barclays Biotech 1×1 Day Format: 1×1 Meetings Date: Tuesday, October […]
Reflections as we prepare for the Jewish New Year
An Open Letter from Uzi Sofer, Alpha Tau’s CEO Dear Alpha Tau Team, As we prepare to welcome the Jewish New Year, I want to pause and reflect with you on the journey that we have made over the past year. Thank God, it has been an extraordinary year for Alpha Tau. Many years of […]
לקראת סיומה של שנת תשפ״ו וכניסתה של שנת תשפ״ז
מכתב מעוזי סופר, מנכ”ל אלפא תאו, לסיומה של שנת תשפ״ו וכניסתה של שנת תשפ״ז עובדות ועובדי אלפא תאו היקרים, לקראת סיומה של שנת תשפ״ו וכניסתה של שנת תשפ״ז, אני רוצה לעצור לרגע ולהביט יחד אתכם על הדרך שעשינו בשנה האחרונה. ברוך השם זו הייתה שנה יוצאת דופן עבור אלפא תאו. שנה שבה שנים של מחקר, […]
Alpha Tau to Participate in September Investor Conferences
JERUSALEM, September 2, 2026 — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in September 2026. Event: Citi’s 2026 Biopharma Back to School Conference Format: 1×1 Meetings Date: […]
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
Jerusalem, August 31, 2026 — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the completion of patient enrollment in its IMPACT study (Intratumoral Pancreatic Alpha Combination Trial) – a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy for […]
Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer
A Conversation with Prof. Aron Popovtzer, MD Prof. Aron Popovtzer, MD Chair, Sharett Institute of Oncology, and Co-Chair, Hadassah Cancer Research Institute Hadassah University Medical Center, Jerusalem With Gideon D. Matthews PhD, Commercial VP, Alpha Tau Medical Introduction Every year, roughly 890,000 people around the world are told they have a cancer of the mouth, […]
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
JERUSALEM, August 10, 2026 – Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported second quarter 2026 financial results and provided a corporate update. “The second quarter of 2026 was without question the busiest and most consequential period in Alpha Tau’s […]
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Jerusalem, August 10, 2026 — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets. […]
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study’s Pre-Specified Threshold for Success
Jerusalem, July 21, 2026 — Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”) (Nasdaq: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced and metastatic head and neck squamous […]
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Jerusalem, July 15, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the successful treatment of the first patient in the ADMIRE (Alpha DaRT Management for Immunocompromised patients with REcurrent cSCC) study – a clinical trial evaluating intratumoral Alpha DaRT for […]